Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Immunol Lett. 2017 Oct 3;191:47–54. doi: 10.1016/j.imlet.2017.08.024

Figure 1.

Figure 1

Generation of CT26 cell lines producing excess, endogenous, or decreased TGF-β.

A CT26 colon cancer cell line was genetically engineered (see Methods) to express TGF-β (CT26-TGF-β) or TGF-β dominant-negative receptor (CT26-TGF-β-R). Neomycin empty cassette was used to generate the control cell line, CT26-neo. A) Schematic representation of the in vitro experiments performed. B) The concentration of the active form (acidified) of TGF-β present in the tumor cell culture media measured by ELISA. C) The concentration of TGF-β-R in the tumor culture media measured by ELISA.